Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• UBR5 is a nuclear phosphoprotein with largely unknown functions.
• UBR5 amplifications and overexpression are found in over 20% of human breast cancers, correlating with reduced patient survival.

Purpose of the Study:

• To elucidate the functional role of UBR5 in breast cancer pathophysiology and immunobiology.
• To investigate UBR5's mechanisms in tumor growth, metastasis, and immune evasion.
• To explore the therapeutic potential of targeting UBR5, particularly in combination with PD-L1 inhibitors.

Main Methods:

• In vitro and in vivo experimental models of breast cancer.
• Analysis of UBR5 expression and genetic lesions in patient cohorts.
• Investigation of UBR5's role in immune cell interactions (CD8+ T lymphocytes).
• Assessment of UBR5's transcriptional control over epithelial-mesenchymal transition (EMT) regulators (ID1, ID3).
• Evaluation of combined UBR5 and PD-L1 targeting in preclinical models.

Main Results:

• UBR5 functions as an oncoprotein, promoting breast cancer growth and metastasis.
• UBR5 inhibits the cytotoxic CD8+ T lymphocyte response via paracrine interactions.
• UBR5 facilitates metastasis through transcriptional control of ID1 and ID3, key EMT regulators.
• Simultaneous targeting of UBR5 and PD-L1 demonstrated significant therapeutic benefits in tumor-bearing hosts.

Conclusions:

• UBR5 is a critical driver of aggressive breast cancer, impacting both tumor growth and immune evasion.
• Targeting UBR5 offers a novel therapeutic strategy for breast cancers resistant to conventional treatments.
• Combined UBR5 and PD-L1 inhibition presents a promising avenue for developing advanced immunotherapies.